Cargando…

Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation

PURPOSE: To analyze the clinical characteristics of Pneumocystis pneumonia (PCP) in renal transplant recipients, identify early sensitivity indicators, and optimize clinical strategies. PATIENTS AND METHODS: We retrospectively analyzed clinical data for 24 patients with confirmed PCP who underwent r...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tiantian, Shi, Junqin, Xu, Fei, Xu, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955634/
https://www.ncbi.nlm.nih.gov/pubmed/32021322
http://dx.doi.org/10.2147/IDR.S234039
_version_ 1783486974146904064
author Li, Tiantian
Shi, Junqin
Xu, Fei
Xu, Xiaoling
author_facet Li, Tiantian
Shi, Junqin
Xu, Fei
Xu, Xiaoling
author_sort Li, Tiantian
collection PubMed
description PURPOSE: To analyze the clinical characteristics of Pneumocystis pneumonia (PCP) in renal transplant recipients, identify early sensitivity indicators, and optimize clinical strategies. PATIENTS AND METHODS: We retrospectively analyzed clinical data for 24 patients with confirmed PCP who underwent renal transplantation (RT) between 2010 and 2019, encompassing a mean follow-up of 29 (range, 11–49) d. RESULTS: A 71% incidence was observed for PCP during the first 6 months after RT. Progressive dyspnea (79%) was the most common symptom, followed by fever (75%) and dry cough (67%). In the initial phase of PCP, the most frequent computerized tomography (CT) finding was the presence of symmetric, apically distributed ground-glass opacities. Nine of 11 patients (82%) were diagnosed by induced sputum testing, 14 of 17 (82%) by bronchoalveolar lavage, and 1 of 24 (4%) by sputum smear. The 1,3-β-D-glucan level was elevated (mean, 259.16 ± 392.34 pg/mL) in 80% of patients, while 75% had elevated C-reactive protein levels (median, 37.85 mg/L). Two of 18 patients (11%) were positive for cytomegalovirus. All patients were treated with trimethoprim-sulfamethoxazole (3 doses of 1–6 g/kg) and third-generation cephalosporin or moxifloxacin monotherapy to prevent bacterial infection. The methylprednisolone dose (40–400 mg/d) varied according to illness. Most patients were treated using a nasal cannula or oxygen mask, and 2 by mechanical ventilation. CT showed improved lesions after treatment, and completely absorbed lesions or residual fibrosis at follow-up. The mean hospitalization cost was 14,644.73 ± 11,101.59 RMB. CONCLUSION: Peak PCP incidence occurred during the first 6 months after surgery. Progressive dyspnea, fever, and dry cough are important indicators for PCP. Bilateral and diffuse ground-glass opacities involving both lung apexes are often the first indication for PCP diagnosis. Induced sputum testing may be the method-of-choice for pathogen detection. The cure rate can be improved through early antipathogen, glucocorticoid, and preventive anti-infection therapies, as well as respiratory support.
format Online
Article
Text
id pubmed-6955634
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69556342020-02-04 Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation Li, Tiantian Shi, Junqin Xu, Fei Xu, Xiaoling Infect Drug Resist Original Research PURPOSE: To analyze the clinical characteristics of Pneumocystis pneumonia (PCP) in renal transplant recipients, identify early sensitivity indicators, and optimize clinical strategies. PATIENTS AND METHODS: We retrospectively analyzed clinical data for 24 patients with confirmed PCP who underwent renal transplantation (RT) between 2010 and 2019, encompassing a mean follow-up of 29 (range, 11–49) d. RESULTS: A 71% incidence was observed for PCP during the first 6 months after RT. Progressive dyspnea (79%) was the most common symptom, followed by fever (75%) and dry cough (67%). In the initial phase of PCP, the most frequent computerized tomography (CT) finding was the presence of symmetric, apically distributed ground-glass opacities. Nine of 11 patients (82%) were diagnosed by induced sputum testing, 14 of 17 (82%) by bronchoalveolar lavage, and 1 of 24 (4%) by sputum smear. The 1,3-β-D-glucan level was elevated (mean, 259.16 ± 392.34 pg/mL) in 80% of patients, while 75% had elevated C-reactive protein levels (median, 37.85 mg/L). Two of 18 patients (11%) were positive for cytomegalovirus. All patients were treated with trimethoprim-sulfamethoxazole (3 doses of 1–6 g/kg) and third-generation cephalosporin or moxifloxacin monotherapy to prevent bacterial infection. The methylprednisolone dose (40–400 mg/d) varied according to illness. Most patients were treated using a nasal cannula or oxygen mask, and 2 by mechanical ventilation. CT showed improved lesions after treatment, and completely absorbed lesions or residual fibrosis at follow-up. The mean hospitalization cost was 14,644.73 ± 11,101.59 RMB. CONCLUSION: Peak PCP incidence occurred during the first 6 months after surgery. Progressive dyspnea, fever, and dry cough are important indicators for PCP. Bilateral and diffuse ground-glass opacities involving both lung apexes are often the first indication for PCP diagnosis. Induced sputum testing may be the method-of-choice for pathogen detection. The cure rate can be improved through early antipathogen, glucocorticoid, and preventive anti-infection therapies, as well as respiratory support. Dove 2020-01-08 /pmc/articles/PMC6955634/ /pubmed/32021322 http://dx.doi.org/10.2147/IDR.S234039 Text en © 2020 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Tiantian
Shi, Junqin
Xu, Fei
Xu, Xiaoling
Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation
title Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation
title_full Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation
title_fullStr Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation
title_full_unstemmed Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation
title_short Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation
title_sort clinical characteristics of pneumocystis pneumonia after parental renal transplantation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955634/
https://www.ncbi.nlm.nih.gov/pubmed/32021322
http://dx.doi.org/10.2147/IDR.S234039
work_keys_str_mv AT litiantian clinicalcharacteristicsofpneumocystispneumoniaafterparentalrenaltransplantation
AT shijunqin clinicalcharacteristicsofpneumocystispneumoniaafterparentalrenaltransplantation
AT xufei clinicalcharacteristicsofpneumocystispneumoniaafterparentalrenaltransplantation
AT xuxiaoling clinicalcharacteristicsofpneumocystispneumoniaafterparentalrenaltransplantation